GlassScriptPhysician profile
Lance Micheel Freeman
NPI 1205097565
$3,804.96
in general payments reported to CMS, 2019-2025
36 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $159 · 2021: $67.77 · 2022: $665 · 2023: $490 · 2024: $650 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.62 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $498.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $358.74 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $323.85 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $319.05 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $287.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $268.90 | 2019-2025 | |
| Lilly USA, LLC | $212.10 | 2022-2024 | Zepbound |
| Ascendis Pharma Endocrinology INC | $164.16 | 2024-2025 | Yorvipath |
| Abbvie INC. | $141.77 | 2019-2025 | |
| Horizon Therapeutics Plc | $125.93 | 2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $125.74 | 2019-2022 | |
| Corcept Therapeutics | $120.33 | 2020-2023 | Korlym |
| Medtronic, INC. | $98.89 | 2022-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $79.36 | 2023-2025 | Recorlev |
| Amarin Pharma, INC. | $69.23 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.